Therapeutic administration of ACT-1004-1239 or siponimod, given at doses leading to clinically relevant pharmacodynamic effects, namely maximal plasma CXCL12 increase and maximal lymphopenia over 24 h, respectively, demonstrated similar efficacy on EAE clinical scores and relapse rate. The gene discussed is CXCL12; the disease is lymphopenia.